Jupiter Neurosciences, Inc.

JUNS

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001679628

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $5.6M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	late filer, thin data, degenerate inputs not computable: short runway, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Apr 1, 2026 224 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$2.34 2026-11-02; market equity $1.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 1, 2026

other sections of this Annual Report on Form 10-K, includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data and we do not make any representation as to the accuracy of the information.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 49.8						
Gross profitability	0.3%	32.3%		92.3	365	2025-12-31
Return on invested capital	not computable	9.3%				

one or more required annual facts are missing						
Accruals ratio	(54.9%)	(6.6%)		7.4	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 88.3						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(34.36)	(0.35)		83.5	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	0.65x	2.95x		93.2	826	2025-12-31
Growth and financing, sleeve percentile 50.4						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 2						
Net share issuance, one year	9.6%	2.5%		50.4	628	2026-03-31

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-02 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(97.7%)	(1.9%)	0
Distance from 52-week high	(97.9%)	(28.5%)	1
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	(0.21)	0.27	5
Sales to price	0.01	0.29	7
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(3.95)	(0.19)	0

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	89 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$82,046

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$17,565	2025-12-31	2026-04-01	10-K	26-014687
2	assets	us-gaap:Assets	$5.6M	2025-12-31	2026-04-01	10-K	26-014687
3	net income	us-gaap:NetIncomeLoss	-$8.6M	2025-12-31	2026-04-01	10-K	26-014687
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.4M	2025-12-31	2026-04-01	10-K	26-014687
5	assets	us-gaap:Assets	$6.2M	2024-12-31	2026-04-01	10-K	26-014687
6	current assets	us-gaap:AssetsCurrent	$4.8M	2025-12-31	2026-04-01	10-K	26-014687
7	current liabilities	us-gaap:LiabilitiesCurrent	$7.4M	2025-12-31	2026-04-01	10-K	26-014687
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$34.7M	2025-12-31	2026-04-01	10-K	26-014687
9	operating income	us-gaap:OperatingIncomeLoss	-$8.9M	2025-12-31	2026-04-01	10-K	26-014687
10	book equity	us-gaap:StockholdersEquity	-$1.8M	2025-12-31	2026-04-01	10-K	26-014687
11	liabilities	us-gaap:Liabilities	$7.4M	2025-12-31	2026-04-01	10-K	26-014687
12	revenue	us-gaap:Revenues	$21,796	2025-12-31	2026-04-01	10-K	26-014687
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,281,252	2026-03-31	2026-04-01	10-K	26-014687
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	33,103,860	2025-03-28	2025-03-28	10-K	25-001261

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.